Multimedia update - albireo announces fda approval of bylvay™ (odevixibat), the first drug treatment for patients with progressive familial intrahepatic cholestasis (pfic)

– only once-daily drug indicated for the treatment of pruritus in pfic –

ALBO Ratings Summary

ALBO Quant Ranking